title: A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
authors.affiliation: Emory University, Atlanta, GA 30322.
authors.forename: W R
authors.initials: WR
authors.lastname: Vogler
authors.forename: E
authors.initials: E
authors.lastname: Velez-Garcia
authors.forename: G
authors.initials: G
authors.lastname: Omura
authors.forename: M
authors.initials: M
authors.lastname: Raney
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin